Drug
Mra
Mra: highest development phase Phase 3, developed by Chugai. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Chugai
Trials
| Drug | Phase | Indication |
|---|---|---|
| MRA(Tocilizumab) NCT00144664 | Phase 3 | Systemic Juvenile Idiopathic Arthritis |
| MRA (Tocilizumab) NCT00144508 | Phase 3 | Rheumatoid Arthritis |
| MRA(Tocilizumab) NCT00144612 | Phase 3 | Systemic Juvenile Idiopathic Arthritis |
| MRA(Tocilizumab) NCT00144599 | Phase 3 | Systemic Juvenile Idiopathic Arthritis |
| MRA(Tocilizumab) NCT00144625 | Phase 3 | Polyarticular Juvenile Idiopathic Arthritis |
| MRA(Tocilizumab) NCT00380601 | Phase 3 | Rheumatoid Arthritis |
| MRA(Tocilizumab) NCT00144521 | Phase 3 | Rheumatoid Arthritis |
| MRA (Tocilizumab) NCT00144534 | Phase 3 | Rheumatoid Arthritis |
| MRA(Tocilizumab) NCT00144651 | Phase 2 | Rheumatoid Arthritis |
| MRA(Tocilizumab) NCT00144560 | Not Applicable | Rheumatoid Arthritis |
Latest
No recent events.
Follow Mra on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.